VICC, Tempus launch new data initiative to help cancer patientsby Doug Campbell | Jan. 18, 2018, 9:47 AM
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients.
As part of the initial research project, Tempus will use its Tempus O platform to collect and structure clinical data from the cancer center’s electronic health record. Tempus also will provide next generation sequencing and analysis for a subset of patients in order to identify actionable gene alterations.
“The ability to synthesize and make sense of clinical and molecular data is key to personalized medicine efforts,” said Eric Lefkofsky, founder and CEO of Tempus. “We are pleased to bring our state-of the-art solution to the team at Vanderbilt-Ingram Cancer Center and other top academic centers, hospital systems, associations and health care providers across the country. The Tempus platform will unlock critical data, accelerating discovery and ultimately improving patient care.”
In oncology, and across healthcare more broadly, datasets are small and sometimes disorganized. In order to usher in the age of precision medicine, Tempus built a series of data pipelines to collect, cleanse and analyze data at scale. These data pipelines in turn are powering a variety of clinical and research applications to drive clinical decision support and leading-edge academic research.
“Empowering Vanderbilt-Ingram researchers and physicians with data, tools and evidence to help inform care and accelerate discoveries that benefit patients is a top priority,” said Jennifer Pietenpol, PhD, Executive Vice President for Research at Vanderbilt University Medical Center and director of VICC. “Collaborating with Tempus will allow the Vanderbilt-Ingram team to gain a deeper understanding of a patient’s cancer and its genetic and molecular drivers, with a goal of improving patient outcomes.”